Health
Novo Says Ozempic ‘Very Likely’ Target for Next US Price Cut
- Blockbuster diabetes drug likely to see reduction in 2027
- Novo ready to engage in US government talks, executive says
Ozempic has a list price of $968.52 a month in the US.
Photographer: George Frey/BloombergThis article is for subscribers only.
Ozempic, the blockbuster diabetes shot made by Novo Nordisk A/S, is “very likely” to be one of the next drugs targeted for a price cut in bargaining with the US government’s Medicare program, a company executive said.
The Inflation Reduction Act, which allows the US to directly negotiate drug prices with manufacturers for the first time, last month slashed the cost of 10 of the world’s biggest medicines by 38% to 79% for 2026. The 15 drugs targeted for the next round are expected to be named by early next year, drawing widespread speculation about which treatments will be in the government’s crosshairs.